FDA confirms path to DEP HER2 first-in-human study
Filed with ASX · · 3 pages · English
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- AGM Chair address and CEO presentation
- Upfront payment of USD $5.5 million received from Genentech
- SPL: Research & Option Agreement with Radiopharm Theranostics
Later from Starpharma
- DEP radiopharmaceutical data supports patent application
- Positive DEP HER2-Lu preclinical data support Phase 1 entry
- DEP milestone triggers partner option fee
- Quarterly Activities Report and Appendix 4C
- Fully Underwritten Entitlement Offer to Raise $32 Million
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma